Schrödinger, Inc. (SDGR)
NASDAQ: SDGR · Real-Time Price · USD
19.73
-0.03 (-0.15%)
Dec 24, 2024, 1:00 PM EST - Market closed
Schrödinger Revenue
Schrödinger had revenue of $35.29M in the quarter ending September 30, 2024, a decrease of -17.10%. This brings the company's revenue in the last twelve months to $193.35M, down -3.03% year-over-year. In the year 2023, Schrödinger had annual revenue of $216.67M with 19.73% growth.
Revenue (ttm)
$193.35M
Revenue Growth
-3.03%
P/S Ratio
7.40
Revenue / Employee
$223,008
Employees
867
Market Cap
1.44B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AtriCure | 447.57M |
InMode | 423.75M |
Phreesia | 405.14M |
Kiniksa Pharmaceuticals International, | 384.10M |
Immunocore Holdings | 296.31M |
Arcus Biosciences | 263.00M |
RxSight | 128.29M |
Nurix Therapeutics | 56.42M |
SDGR News
- 8 days ago - Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Schrödinger Broadens and Accelerates Predictive Toxicology Initiative - Business Wire
- 6 weeks ago - Schrödinger (SDGR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Schrödinger Reports Third Quarter 2024 Financial Results - Business Wire
- 7 weeks ago - Schrödinger to Present at Jefferies London Healthcare Conference - Business Wire
- 7 weeks ago - Schrödinger to Announce Third Quarter 2024 Financial Results on November 12 - Business Wire
- 2 months ago - Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium - Business Wire
- 2 months ago - Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium - Business Wire